Women's Health Has a Diagnostic Blind Spot

Conditions like endometriosis, PCOS, perimenopause complications, and fertility issues are routinely misdiagnosed or take years to identify because most clinical research and diagnostic tooling were built around male biology. Xella Health, founded in San Francisco, is building a precision-health platform designed explicitly for female biology to close that gap.

What They're Building

Xella's core innovation is first-of-its-kind, AI-powered multi-omic testing that combines peripheral blood with menstrual fluid as a diagnostic input — an underused biological sample that can reveal insights standard blood panels miss. The platform aims to uncover the root causes behind women's health concerns across fertility, perimenopause, endometriosis, PCOS, and early cancer detection, then pairs findings with concierge-style care. The company says its platform is built to detect and treat 130+ often-misdiagnosed women's health conditions.

Growth

Xella closed its $3.7M pre-seed in January 2026 (led by Precursor Ventures, with Capital F, Ulu Ventures, and angels), publicly launched on June 24, 2026, and reported a waitlist of nearly 10,000 people ahead of its Spring 2026 platform rollout.